Clarkston Life Sciences Industry Lead Discusses Implications of Novo Catalent Takeover
October 31, 2024 | Clarkston partner and life sciences industry lead, Janel Firestein discusses how Novo’s acquisition efforts are coming under fire from a potential competitor, Roche, and how the insider information Novo would gain with regard to the burgeoning field could cause some conflicts along the way. View a few of her quotes below and the full article here.
Backlash builds against Novo’s Catalent takeover
“Reduced production access aside, there would still be concerns the acquisition would provide Novo Nordisk with substantial insights to production processes, operational strategies and manufacturing bottlenecks, which in turn would give them a considerable competitive advantage.”
“The highly competitive nature of this industry, the sharp rise in GLP-1 drugs, and competitive dynamics therein and already-constrained supply chains has forced even more pressure on this deal.”